Abstract:Toll-like receptors (TLRs), as the most important pattern recognition receptors in innate immunity, play a pivotal role in inducing immune response through recognition of microbial invaders or specific agonists. Recent studies have suggested that TLRs could serve as important regulators in the development of a variety of cancer. However, increasing evidences have shown that TLRs may display quite opposite outcomes in cancer development. Although several potential therapeutic Toll-like receptor ligands have been found, the mechanism and therapy prospect of TLRs in cancer development has to be further elucidated to accelerate the clinical application. By performing a systematic review of the present findings on TLRs in cancer immunology, we attempted to evaluate the therapeutic potential of TLRs in cancer therapy and elucidate the potential mechanism of cancer progress regulated by TLR signaling and the reported targets on TLRs for clinical application. An electronic databases search was conducted in PubMed, Chinese Scientific Journal Database, and Chinese Biomedical Literature Database from their inception to February 1, 2016. The following keywords were used to search the databases: Toll-like receptors, cancer therapy, therapeutic target, innate immunity. Of 244 studies that were identified, 97 nonrelevant studies were excluded. In total, 147 full-text articles were assessed, and from these, 54 were excluded as they did not provide complete key information. Thus, 93 studies were considered eligible and included in the analysis. According to the data from the included trials, 14 TLR ligands (77.8%) from 82 studies have been demonstrated to display antitumor property in various cancers, whereas 4 ligands (22.2%) from 11 studies promote tumors. Among them, only 3 TLR ligands have been approved for cancer therapy, and 9 ligands were in clinical trials. In addition, the potential mechanism of recently reported targets on TLRs for clinical application was also evaluated in this review. We show that targeting TLRs in cancer immunotherapy is a promising strategy for cancer therapy, and the specific TLR ligands, either alone or combination, exhibit antitumor potential.

Targeting Toll-Like Receptors on T Cells As a Therapeutic Strategy Against Tumors.

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Genetically engineered T cells for cancer immunotherapy

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.

Toll-like receptor-targeted anti-tumor therapies: Advances and challenges

T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells

Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics

Toll-like Receptors Expressed in Tumor Cells: Targets for Therapy

Toll-like Receptor-Targeted Nanoparticles: A Powerful Combination for Tumor Immunotherapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

The Role of Toll-Like Receptor in Inflammation and Tumor Immunity

Targeting cancers through TCR-peptide/MHC interactions

Application potential of toll-like receptors in cancer immunotherapy: Systematic review.

Target tumor microenvironment by innate T cells

Immunotherapeutic Implications of Toll-like Receptors Activation in Tumor Microenvironment

The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy

Targeting TNFR2 for cancer immunotherapy: recent advances and future directions

Targeting Tumor Cells with Antibodies Enhances Anti-Tumor Immunity

Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer

Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity

Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade